Duchenne muscular dystrophy (DMD) + Becker muscular dystrophy (BMD)

What changes during this transition

Duchenne and Becker muscular dystrophies are X-linked recessive disorders caused by mutations in DMD (Xp21.2-p21.1) — the largest gene in the human genome at ~2.4 megabases across 79 exons. Out-of-frame mutations producing absent or severely reduced dystrophin protein cause DUCHENNE (severe form, incidence ~1/3,500–5,000 male births); in-frame mutations producing partial-function dystrophin cause BECKER (milder, later-onset, often diagnosed in adulthood). Dystrophin normally links cytoskeletal actin to the dystrophin-associated glycoprotein complex, stabilizing the sarcolemma during muscle contraction; its absence produces progressive fiber necrosis, fat and fibrotic replacement, and a defined clinical trajectory. Pre-treatment-era DMD progression: delayed motor milestones and Gowers sign at 3–5 years; loss of ambulation typically 10–13 years; teen scoliosis, contractures, restrictive lung disease; late teens/20s dilated cardiomyopathy and respiratory failure; death historically in 20s–30s. Modern multidisciplinary care has extended median survival to 30s–40s+, and CARDIOMYOPATHY is now the leading mortality cause in the modern era. Females are typically carriers; ~5–10% manifesting carriers have variable symptoms, and a subset have cardiomyopathy without overt muscle involvement. The therapy landscape has transformed continually. CORTICOSTEROIDS (prednisone, deflazacort) remain the historical foundation — they slow progression, prolong ambulation, and delay cardiac/respiratory complications, with significant side-effect burden (growth failure, osteoporosis, weight gain, behavioral effects, cataracts, glucose intolerance). VAMOROLONE (Agamree, ReveraGen/Catalyst) was FDA-approved October 2023 as a dissociative steroid with reduced side effects for DMD ≥2 years. EXON-SKIPPING ANTISENSE OLIGONUCLEOTIDES restore reading frame for mutation-specific subpopulations: eteplirsen (Exondys 51, Sarepta, FDA Sep 2016, exon 51), golodirsen (Vyondys 53, Sarepta, FDA Dec 2019), viltolarsen (Viltepso, NS Pharma, FDA Aug 2020, exon 53), casimersen (Amondys 45, Sarepta, FDA Feb 2021, exon 45) — all weekly IV with modest dystrophin restoration under accelerated-approval pathway. DELANDISTROGENE MOXEPARVOVEC (Elevidys, Sarepta) — AAV-vectored micro-dystrophin gene therapy — was FDA-approved June 2023 and expanded June 2024 to all DMD ≥4 years including non-ambulatory; single IV infusion, ~$3.2M list price, transformative for community despite the EMBARK Phase 3 primary-endpoint miss and ongoing controversy. GIVINOSTAT (Duvyzat, Italfarmaco) — first HDAC inhibitor for ambulatory DMD ≥6 years — was FDA-approved March 2024. ATALUREN (Translarna, PTC Therapeutics) for nonsense mutations is EMA-conditional; FDA has rejected it multiple times. APITEGROMAB (Scholar Rock, anti-myostatin) is in Phase 3 for DMD. Multidisciplinary supportive care — physical and occupational therapy, contracture prevention, cough assist and BiPAP, annual cardiac surveillance with ACE inhibitor/ARB and beta-blocker initiated early, scoliosis surgery, osteoporosis and puberty management, speech/swallowing, nutrition, psychosocial — is structured by the 2018 DMD Care Considerations and delivered through PPMD's Certified Duchenne Care Center network. Patient advocacy is led by Parent Project Muscular Dystrophy (PPMD), Muscular Dystrophy Association (MDA), CureDuchenne, Duchenne Foundation, and HOPE / Cure Becker for the Becker population. Editorially, DMD families are an aggressively targeted community peptide market. BPC-157 is marketed as 'muscle healing/repair' against parental hope for muscle preservation; CJC-1295, ipamorelin, and tesamorelin are framed as 'muscle preservation/growth' against the very real growth failure that chronic corticosteroids produce in young children — sometimes with a mechanistically incorrect 'myostatin inhibition' overlay, when the actual anti-myostatin program in DMD is apitegromab in Phase 3, not GH secretagogues. IGF-1 peptides are marketed as 'neurotrophic/muscle preservation' despite disappointing IGF-1-axis trial results in DMD. NMN is marketed against the genuine mitochondrial dysfunction component of dystrophin-deficient muscle without DMD-specific evidence. BPC-157 + TB-500 stacks reach families directly. None of these are characterized in DMD-population trials; none have pediatric pharmacology in this disease; none have safety profiles in the cardiomyopathy + steroid + ASO/gene-therapy context most DMD children live inside. The load-bearing interventions are the regulated ones — corticosteroids, vamorolone, exon-skipping ASOs, Elevidys, givinostat, apitegromab in Phase 3 — delivered through PPMD's Certified Duchenne Care Center network with coordinated cardiology, pulmonology, endocrinology, orthopedic, and psychosocial support. The substrate exists so that when families ask /ask about community peptides for their child, the answer honors their grief without abandoning the editorial line: this is a vulnerable pediatric population, the disease is devastating, families are desperate, and that is precisely why the answer has to be honest about what is and isn't being studied. Seventy-fifth deliberate non-elevation of community peptides.